A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone[OCX 0191] (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs OCX 191 (Primary)
- Indications Cancer; Colorectal cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 02 Jan 2008 Status changed from in progress to completed.
- 27 Sep 2005 New trial record.